Group 1 - Aike Cyber (688719.SH) shareholders Dachen Chuangtong and Dachen Chuanghong reduced their holdings by 2,298,151 shares, accounting for 1.99% of the total share capital, and did not complete the planned reduction [1] - Benchuan Intelligent (300964.SZ) controlling shareholder Dong Xiaojun reduced his holdings by 355,787 shares, accounting for 0.4582% of the total share capital, bringing his shareholding down to 21.64% [1] - Changlian Co., Ltd. (603648.SH) completed its reduction plan by selling 3,624,050 shares, which is 1% of the total share capital [1] Group 2 - Chuan Yi Technology (002866.SZ) controlling shareholder Zou Weimin and his concerted party reduced their holdings, with Zou's shareholding dropping to 48.53% [2] - Daoshi Technology (300409.SZ) controlling shareholder Rong Jihua plans to reduce his holdings by up to 15,416,611 shares, accounting for 1.97% of the total share capital [2] - Electric Alloy (300697.SZ) completed its reduction plan by selling 2,741,390 shares, which is 0.63% of the total share capital [2] Group 3 - Fujirei (688272.SH) shareholders Suzhou Kongkong, Suzhou Zhaorong, and Shanghai Zhaoren reduced their holdings by 1,215,618 shares, 1,463,490 shares, and 44,944 shares, accounting for 1.60%, 1.93%, and 0.06% of the total share capital respectively [3] - Gaoweida (300465.SZ) controlling shareholder Yingtan Yinggao Investment Consulting Co., Ltd. reduced its holdings by 4,261,700 shares, accounting for 0.96% of the total share capital, bringing its shareholding down to 22.00% [3] - Haizheng Materials (688203.SH) shareholder Sinopec Capital plans to reduce its holdings by up to 3,525,600 shares, accounting for 1.74% of the total share capital [3] Group 4 - Hangyu Micro (300053.SZ) shareholder Yan Jun reduced his holdings by 3,930,000 shares, accounting for 0.56% of the total share capital [4] - He Shi Eye Hospital (301103.SZ) shareholder Advanced Manufacturing Industry Investment Fund plans to reduce its holdings by up to 3,106,074 shares, accounting for 2% of the total share capital [4] - He Yuan Gas (002971.SZ) shareholder Baishide Chuangye completed its reduction plan by selling 854,064 shares, which is 0.415% of the total share capital [4] Group 5 - Huaren Health (301408.SZ) shareholder Saifu Investment reduced its holdings by 2,107,696 shares, accounting for 0.53% of the total share capital [5] - Jiangsu Boyun (301003.SZ) shareholder Gong Wei reduced his holdings by 1,558,900 shares, accounting for 1.57% of the total share capital [5] - Jeya Co., Ltd. (301108.SZ) shareholders Mingyuan Fund and its concerted party did not reduce their holdings, and the reduction plan period expired [5] Group 6 - Longxin General (603766.SH) directors plan to reduce their holdings by up to 350,000 shares and 100,000 shares, accounting for 0.0170% and 0.0049% of the total share capital respectively [6] - Ruchuang Micro-Nano (688002.SH) shareholder Li Weicheng plans to reduce his holdings by up to 8,000,000 shares, accounting for 1.75% of the total share capital [6] - Shilan Micro (600460.SH) shareholder Luo Huabing plans to reduce his holdings by up to 500,000 shares, accounting for 0.03005% of the total share capital [6] Group 7 - Tongfu Microelectronics (002156.SZ) shareholder National Integrated Circuit Industry Investment Fund reduced its holdings by 15,175,969 shares, accounting for 1% of the total share capital [7] - Wangzi New Materials (002735.SZ) controlling shareholder Wang Jinjun reduced his holdings by 9,717,874 shares, accounting for 2.54% of the total share capital [7] - Xingye Co., Ltd. (603928.SH) shareholder Shen Genzhen reduced his holdings by 2,620,000 shares, accounting for 1.00% of the total share capital [7] Group 8 - Yikang Co., Ltd. (301085.SZ) controlling shareholder concerted party reduced its holdings by 633,700 shares, accounting for 0.73% of the total share capital [8] Group 9 - Yiming Pharmaceutical (002826.SZ) major shareholder Zhou Zhan reduced his holdings by 3,586,777 shares, accounting for 1.88% of the total share capital [9] - Yiming Pharmaceutical (002826.SZ) director Xi Ke reduced his holdings by 283,862 shares, accounting for 0.15% of the total share capital [9] - Youyan Powder Materials (688456.SH) concerted party reduced its holdings by 1,030,000 shares, accounting for 0.99% of the total share capital [9] Group 10 - Zhongma Transmission (603767.SH) directors plan to reduce their holdings through block trading and centralized bidding [10] - Zhongqi Co., Ltd. (301215.SZ) shareholder Jiangsu Yueda Group did not reduce its holdings, and the reduction plan period expired [10]

Core Viewpoint - As of June 30, 2025, Zhejiang Haizheng Biomaterials Co., Ltd. (海正生材) reported a closing price of 12.66 yuan, reflecting a decrease of 0.24% with a turnover rate of 5.89% and a trading volume of 69,300 shares, amounting to a transaction value of 87.1 million yuan [1]. Trading Information Summary - On June 30, 2025, the fund flow for Haizheng Biomaterials was as follows: - Net outflow of main funds was 14.64 million yuan, accounting for 16.81% of the total transaction value - Net inflow of retail funds was 11.67 million yuan, representing 13.39% of the total transaction value - Net inflow of speculative funds was 2.97 million yuan, making up 3.41% of the total transaction value [2][4]. Company Announcement Summary - Zhejiang Haizheng Biomaterials announced a shareholder reduction plan: - As of the announcement date, Sinopec Capital held 13,659,494 shares, representing 6.74% of the total share capital - Sinopec Capital plans to reduce up to 3,525,600 shares within three months through block trading, which is no more than 1.74% of the total share capital, with the reduction price determined by market conditions - In the past 12 months, Sinopec Capital has reduced 2,026,780 shares, accounting for 1% of the total share capital, with a reduction price range of 10.17 to 12.02 yuan per share - Sinopec Capital has committed not to transfer or manage the shares held prior to the public offering for 12 months post-listing or three years after completing the business registration [2][4].

Core Viewpoint - The major shareholder, Sinopec Capital, plans to reduce its stake in Zhejiang Haizheng Biomaterials Co., Ltd. due to funding needs for business development, intending to sell up to 3,525,600 shares, which represents no more than 1.74% of the total share capital [1][2]. Group 1: Shareholder Information - Sinopec Capital holds 13,659,494 shares, accounting for 6.74% of the total share capital of the company [1][2]. - The shares held by Sinopec Capital were acquired before the company's initial public offering (IPO) and became tradable on February 19, 2024 [1][2]. Group 2: Reduction Plan Details - The reduction plan allows Sinopec Capital to sell up to 3,525,600 shares within three months starting from fifteen trading days after the announcement [1][2]. - The selling price will be determined based on the market price at the time of the sale [1][2]. - If there are any changes in the company's total share capital due to stock dividends, capital increases, or other corporate actions, the number of shares to be reduced will be adjusted accordingly [1][2]. Group 3: Compliance and Commitments - Sinopec Capital has committed to not transferring or managing the shares held prior to the IPO for a period of twelve months from the listing date or three years from the date of share acquisition, whichever is later [3][4]. - The shareholder will comply with relevant laws and regulations during the reduction process and will ensure timely disclosure of information [4][5].

Company Announcements - Jihua Group's existing product system does not involve brain-computer interface related fields [1] - Prit's plan to invest 1 billion yuan to build a plastic modification materials headquarters and R&D manufacturing base in South China [1][2] - Lian De Equipment won a contract worth 157 million yuan for BOE's 8.6 generation AMOLED production line project [1][2] - Jiadu Technology plans to issue shares (H-shares) overseas and list on the Hong Kong Stock Exchange [1][2] - Longdi Group intends to acquire no more than 20.1667% equity in Jujia Technology [1][4] - New Zhonggang plans to repurchase shares worth 40 million to 80 million yuan [1][4] - Xiaogoods City expects a net profit increase of 12.57% to 17.40% in the first half of the year [1][4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials through block trading [1][4] - Lihua Co., Ltd. intends to reduce its holdings by no more than 3.00% [1][4] - Zhimin Da plans to raise no more than 213 million yuan through a private placement [1][5] - Xiangtong Co. plans to issue corporate bonds not exceeding 4 billion yuan [1][5] Performance Forecasts - Hanyu Pharmaceutical expects a half-year profit of 142 million to 162 million yuan, turning a profit compared to the previous year [4] - Taotao Automotive anticipates a net profit increase of 70.34% to 97.81% in the first half of the year [4] - Weichai Heavy Machinery expects a net profit increase of 40% to 60% in the first half of the year [4] Shareholding Changes - Lihua Co., Ltd.'s actual controller Cheng Lili and his concerted actors plan to reduce their holdings by no more than 3.00% [4] - He Shi Eye Hospital's Advanced Manufacturing Fund plans to reduce its holdings by no more than 2% [4] - Haitan Ruisheng's shareholder He Lin and his concerted actors plan to reduce their holdings by no more than 2.9463% [4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials [4] Other Announcements - Zhimin Da plans to raise no more than 213 million yuan through a private placement [5] - Yuyuan Co. plans to issue corporate bonds not exceeding 40 billion yuan [5] - Jinhongshun has terminated the planning of a major asset restructuring [5]

Mergers and Acquisitions - Yanpai Co., Ltd. plans to acquire 100% equity of TTL and TTL Management Company for approximately €2.9 million, focusing on industrial textile solutions for B2B clients [1] - Landi Group intends to purchase up to 20.17% equity of Ningbo Jujia New Materials Technology Co., Ltd. for a total price not exceeding ¥121 million, as the company specializes in high-performance LCP fiber production [3] Asset Restructuring - Jinhongshun announced the termination of its major asset restructuring plan to acquire 95.79% of New Thinking Motor Co., Ltd. through share issuance and cash payment [2] Shareholding Changes - Haitai Ruisheng's controlling shareholder, He Lin, and his concerted party Zhongyi An plan to reduce their holdings by up to 2.95%, totaling no more than 177.74 million shares [4] - Silan Microelectronics' shareholder, Luo Huabing, plans to reduce his holdings by no more than 500,000 shares, representing up to 0.03% of the company's total equity [5] - Haizheng Shengcai's major shareholder, Sinopec Capital, intends to reduce its holdings by up to 1.74%, totaling no more than 3.5256 million shares [6] Operational Updates - Haiyang Wang confirmed that its operational status is normal and there are no undisclosed significant matters, despite a stock price fluctuation exceeding 20% [7] - Neimeng Yijian reported that its main business has not undergone significant changes, and the external market environment remains stable [10]

证券代码：688203 证券简称：海正生材 公告编号：2025-35 浙江海正生物材料股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露日，浙江海正生物材料股份有限公司（以下简称"公 司"或"海正生材"）持股 5%以上股东中国石化集团资本有限公司（以下 简称"中石化资本"）持有公司股份 13,659,494 股，占公司总股本的 6.74%。 上述股份为公司首次公开发行前取得的股份，并已于 2024 年 2 月 19 日起 上市流通。 减持计划的主要内容 因经营发展资金需求，中石化资本计划拟自本公告披露之日起十五个 交易日后的三个月内，通过大宗交易方式减持不超过 3,525,600 股，占公 司总股本比例不超过 1.74%。上述股份减持价格按减持实施时的市场价格 确定。在减持计划实施期间，公司若发生送股、资本公积金转增股本、增 发新股或配股等变动事项，减持股份数量将根据公司届时最新的总股本数 量及减持计划比例进行相应调整。 1 ...

Group 1 - The major shareholder, China Petroleum & Chemical Corporation Capital Co., Ltd., plans to reduce its holdings by no more than 3.5256 million shares, accounting for no more than 1.74% of the company's total share capital [1] - Currently, China Petroleum & Chemical Corporation Capital holds 13.6595 million shares, representing 6.74% of the company's total share capital [1] - The reduction plan will be executed through block trading within three months after the announcement, starting fifteen trading days from the date of disclosure [1]

Group 1 - The core viewpoint is that the 3D printing industry is entering a rapid development phase, with polylactic acid (PLA) as a key raw material, and its consumption is expected to exceed 40,000 tons in 2024 [1] - Overseas companies dominate the PLA supply in the 3D printing sector, while domestic companies hold a smaller market share; however, the company is positioned as a significant player in driving material upgrades through continuous innovation [1] - The current demand for 3D printing is primarily concentrated in Europe and the United States, with domestic demand starting late but growing quickly; the company aims to capture more incremental market share by serving leading enterprises and enhancing R&D and product quality [1] Group 2 - Specific requirements for PLA in 3D printing materials include adaptability for high-speed printing, rapid cooling, and various colors and visual effects [1] - The global consumption of PLA is projected to be approximately 260,000 tons in 2024, with domestic consumption around 120,000 tons; the market is currently oversupplied, and prices are nearing cost levels, indicating limited future price volatility [1]

Summary of the Conference Call Industry Overview - The polylactic acid (PLA) market is experiencing a significant price decline due to supply and demand dynamics, with capacity utilization rates at only 30%-40% [2][5] - New capacity additions from domestic and international players are expected to further depress prices, although the decline may be limited as prices approach cost levels [2][5] - The global PLA market is dominated by NatureWorks and Total Corbion, with Haizheng Biomaterials holding a significant domestic market share of approximately 43% [2][6][8] Company Insights - Haizheng Biomaterials has seen substantial growth in its consumer-grade FDM 3D printing business since 2023, benefiting from technological innovations by Tuo Zhu Technology [2][11][12] - The company is expanding its production capacity, with plans for a new 150,000-ton biomass project, with the first phase of 75,000 tons expected to begin trial production by the end of the year [7][44] - The company maintains a competitive position in the domestic market, with a focus on enhancing its market share and exploring new applications for PLA [19][29][45] Financial Performance - The overall operational situation of Haizheng Biomaterials in Q2 2025 is reported to be normal, with improvements compared to Q1 [4] - Financial data for the first half of the year will be detailed in the upcoming semi-annual report, with expectations for revenue to remain stable year-on-year, although profit improvement is necessary [42][43] Market Dynamics - The demand for 3D printing materials is rapidly increasing, with projections suggesting a potential reach of 100,000 tons by 2026, driven by applications in industrial manufacturing and medical devices [2][16] - The domestic market for 3D printing materials is expected to grow significantly, with the majority of sales currently focused on the European and American markets [15][21] Competitive Landscape - The global PLA market is characterized by a stable competitive landscape, with major players holding significant market shares [6][19] - Haizheng Biomaterials faces competition from both domestic and international companies, but its focus on quality and service is seen as a way to enhance its market position [19][29] Regulatory and Environmental Factors - Environmental policies have a significant impact on PLA demand, although the implementation of these policies has not been as aggressive as initially anticipated [10][36] - The market for biodegradable products is shifting from a replacement focus to a supplementary one, indicating a high dependency on environmental policies [36] Future Outlook - The company views PLA as a high-quality material with substantial growth potential, particularly in the 3D printing sector [33][45] - The upcoming capacity expansion and ongoing technological advancements are expected to position Haizheng Biomaterials favorably in the market [44][45] Additional Considerations - The company is exploring new applications and high-value products to enhance margins amid cost pressures [37] - The competitive landscape is expected to remain challenging, with price wars and aggressive strategies from competitors [31][43]

Group 1 - The major shareholder, Hunan Zhongqi Dongjian Private Equity Investment Partnership, held 10,457,516 shares, accounting for 5.16% of the total share capital before the reduction plan [1] - The reduction plan was disclosed on March 7, 2025, with the intention to reduce shares due to funding needs, allowing for a maximum reduction of 1% within three months [1] - As of June 16, 2025, the shareholder had completed the reduction of 2,026,780 shares through centralized bidding, resulting in a current holding of 8,430,736 shares, or 4.16% [2][3] Group 2 - The reduction price range was between 9.85 and 15.54 yuan per share, with a total reduction amount of 22,068,414.24 yuan [2] - The actual reduction was consistent with the previously disclosed plan, confirming that the minimum reduction quantity was achieved [3]